Sales of JW Pharmaceutical’s hemophilia drug ‘Hemlibra’ have surged recently. The reimbursement extensions that had been made for the drug in May had increased the number of eligible patients, raising sales by over twofold.

According to the pharmaceuticals research institution IQVIA, Hemlibra’s sales in 1H this year were KRW 5.7 billion, up 61.6% YoY. Hemlibra’s Q1 sales rose 15.3% YoY to KRW 2.1 billion, and Q2 sales rose 112.0% YoY to KRW 3.6 billion.

Hemlibra is a genetic recombinant drug functioning as a routine prophylaxis agent for hemophilia A caused by coagulation factor VIII deficiency. The drug employs the bispecific antibody technology which simultaneously binds to factor IX